ganitumab

09/01/2012 - "This study was to investigate the safety and tolerability of ganitumab in Japanese patients with advanced solid tumors. "
05/20/2012 - "An open-label phase II study was conducted to evaluate the efficacy and safety of ganitumab monotherapy in patients with metastatic Ewing family tumors (EFT) or desmoplastic small round cell tumors (DSRCT). "
07/03/2013 - "CR and ganitumab treatment were initiated one week after tumor injection. "
09/01/2012 - "Ganitumab up to 20 mg/kg was tolerable in Japanese patients with advanced solid tumors. "
09/01/2012 - "The primary objectives were to assess the safety, tolerability, and pharmacokinetics (PK) of ganitumab in Japanese patients with advanced solid tumors. "

10/01/2013 - "Typical clearance and central volume of distribution values were 1.7- and 1.3-fold higher, respectively, in patients with pancreatic cancer than in patients with other advanced solid cancers, resulting in lower ganitumab exposure. "
10/01/2013 - "Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers."
05/01/2015 - "This double-blind, phase 3 study assessed the efficacy and safety of ganitumab combined with gemcitabine as first-line treatment of metastatic pancreatic cancer. "
05/01/2015 - "Ganitumab combined with gemcitabine had manageable toxicity but did not improve OS, compared with gemcitabine alone in unselected patients with metastatic pancreatic cancer. "
05/01/2014 - "Ganitumab 20 mg/kg combined with gemcitabine 1000 mg/m(2) was tolerable and showed an acceptable safety profile in patients with untreated metastatic pancreatic cancer."

10/01/2014 - "Ganitumab for the treatment of small-cell lung cancer."
11/01/2017 - "A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer."
11/01/2017 - "In this randomized, double-blind, placebo-controlled phase 1b/2 study we assessed the efficacy/safety of rilotumumab or ganitumab combined with etoposide and carboplatin or cisplatin as first-line treatment in patients with extensive stage small-cell lung cancer (ES-SCLC). "

01/01/2023 - "The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models."
01/01/2023 - "Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma."

06/01/2014 - "The effects of ganitumab were tested in vitro against a panel of 23 established ovarian cancer cell lines. "
06/01/2014 - "Here, we explore the therapeutic potential of ganitumab for the treatment of ovarian cancer. "
06/01/2014 - "Furthermore, ganitumab significantly increased the efficacy of cisplatin in ovarian cancer xenograft models in vivo. "
01/01/2023 - "Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer."
06/01/2014 - "Moreover, assessment of tumor expression of IGF-II, phospho-IGF-IR, or PTEN status may help select patients with ovarian cancer who are most likely to benefit from ganitumab. "